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Abstract 
The history of pediatric allergology (PA) in Europe is relatively youthful, dating back to 1984, when a 
small group of pediatricians founded the European Working Group on Pediatric Allergy and Immu-
nology - later giving rise to ESPACI (European Society on Pediatric Allergology and Clinical Immunol-
ogy). In 1990, the first dedicated journal, Pediatric Allergy and Immunology (PAI), was founded. 
There are striking differences across Europe, and even within European countries, in relation to the 
training pathways for doctors seeing children with allergic disease(s). In a sponsored collaboration 
with the European Academy of Allergy and Clinical Immunology (EAACI) Pediatric Section, the EAACI-
Clemens von Piquet Foundation (CvP) organised in 2016 a workshop on the future of PA with a de-
liberate focus on education, research and networking/advocacy. The delegates representing many 
countries across Europe, have endorsed the concept that optimal care of children with allergic dis-
eases is delivered by pediatricians who have received dedicated training in allergy, or allergists who 
have received dedicated training in pediatrics. In order to meet the needs of children and families 
with allergic disease(s), the pediatric allergist is highly encouraged to develop several networks. Our 
challenge is to reinforce a clear strategic approach to scientific excellence to across our member 
base, to ensure and enhance the relevance of European pediatric research in allergy. With research 
opportunities in basic, translational, clinical, and epidemiological trials, more trainees and trained 
specialists are needed and an exciting time to be a pediatric allergologist. 
 
Key words: allergy, anaphylaxis, asthma, children, drug, food allergy, pediatric allergology, pediat-
rics, training, trial  
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Abbreviations: 
PA: pediatric allergology 
ESPACI: European Society of Pediatric Allergology and Clinical Immunology 
PAI: Pediatric Allergy and Immunology 
EAP: European Academy of Pediatrics 
EPA: European Pediatric Association 
EAACI: European Academy of Allergy and Clinical Immunology 
CvP : Clemens von Piquet Foundation 
UEMS: Union Européenne des Médecins Spécialistes 
MDT: Multi-disciplinary team 
GP: General Practitioner 
AIT: Allergen specific immunotherapy 
PIP: Pediatric investigation plan 
EMA : European Medicines Agency 
ETC-PA: Education Training Committee for Pediatric Allergy 
HCP: Health Care Professionals  
 
Introduction 
 
The history of pediatric allergology (PA) is relatively youthful: in 1984 in Europe a small group of 
pediatricians founded the first European Working Group on Pediatric Allergy and Immunology - later 
giving origin to ESPACI (European Society on Pediatric Allergology and Clinical Immunology) [1]. 
ESPACI was a response to the need for a sub-group within the allergy community focusing on the 
specific unmet needs of infants and children developing atopic disease manifestations. Until that 
time, infants and children with, or at risk of atopic dermatitis, food allergy, asthma, allergic rhinitis, 
and/or drug allergy had only the choice of a general pediatrician, a specialist with a strong back-
ground in adult allergy or a specialist with a special interest but no formal training in allergy. The 
absence of a holistic, family-focused approach to allergic conditions may have resulted in significant 
additional burden with respect to the prevalence and morbidity of atopic diseases in the first years 
of life.  
In the subsequent years, global interest in pediatric allergy research, be it basic, translational and/or 
clinical, grew and so did the focus on research quality. Simultaneously, sessions on pediatric allergy 
at international conferences increased in popularity. In 1990, a dedicated journal, Pediatric Allergy 
and Immunology (PAI), was founded. Now most conferences include a considerable number of pae-
diatric sessions. 
A patchwork of differential recognition for the discipline of PA developed in Europe in accordance 
with the fact that in some countries allergology is recognized as a full specialty, while in others it is 
seen as a subspecialty within e.g. dermatology, ENT, respiratory medicine and paediatrics. Early at-
tempts to harmonise the structure of patient care in this area across Europe were unsuccessful until 
the European Academy of Pediatrics (EAP) officially accepted PA as a certified and acknowledged 
sub-speciality in 1999.  
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The EAACI-Clemens von Piquet Foundation (CvP) is a non-profit foundation established to promote 
research and education in pediatric allergy.  In a sponsored collaboration with the European Acade-
my of Allergy and Clinical Immunology (EAACI) Pediatric Section, CvP organised in Rome, October 
2016, a workshop on the future of PA, with a deliberate focus on education, research and network-
ing/advocacy. Invited delegates were the members of the CvP board and senior and junior repre-
sentatives from EAACI Sections and Interest Groups related to the focus topic. These delegates rep-
resented many countries across Europe and CvP additionally invited other representative paediatric 
allergists. Valuable insights were requested from two experts with backgrounds in paediatric drug 
development, including immunotherapy.  The authors of this paper were all active participants of 
this workshop. The paper represents an official statement of CvP and the EAACI Section on Pediat-
rics. 
 
Status quo in Pediatric Allergology in Europe: 
More than two decades after the EAP officially accepted PA as a certified and acknowledged sub-
specialty within pediatrics, there are still striking differences across Europe in the training pathways 
for doctors seeing children with allergic disease(s). The types of doctors currently engaged in PA in 
Europe can be outlined as followed: 
1. Those fully trained in general paediatrics with (extra) dedicated time in allergy. These are 
pediatricians who have a special interest in allergy and the allergy-dedicated training dura-
tion varies among countries eg in UK where this is known as SPIN (special interest) in allergy 
and tends to be for those who wish to work in secondary service with dedicated allergy clin-
ics.  
2. Those trained where PA is a subspecialty within pediatrics, namely through an (integrated) 
general pediatrics (core) training and full specialist allergy training programme leading to ac-
creditation as pediatric allergists. In these countries, PA is regarded as a full (sub)specialty eg 
Sweden, Turkey, Denmark and UK. Subspecialty paediatric allergy training in the UK is a 3-
year programme approved by the Royal College of Paediatrics and Child Health and subspe-
cialty accreditation is awarded by the General Medical Council; this is the usual route to 
working in a tertiary or academic UK allergy unit. In Turkey, after 5 years of general pediatric 
specialty the pediatric immunology and allergy training is an independent 3 year full special-
ty programme. Of note, in some countries, pediatricians that have been dedicated to seeing 
allergic children for a specified sufficient period of time have been granted accreditation as 
pediatric allergists (such as in Spain with pediatricians consulting allergic children for 5 years 
or more). 
3. Those who have completed core training in adult general medicine and, in some cases, a 
short or equal period of paediatrics, followed by a combined clinical training in child and 
adult allergy. These are allergists and allergy is considered as a full (sub)specialty. Repre-
sentative examples of countries implementing this training system is Greece, Portugal, 
Spain, France and Romania.  
4. A fourth setting exists where allergy is not regarded as specialty and the onus is on the indi-
vidual physician to train themselves to feel confident in seeing children with allergic prob-
lems. This may happen in the case of adult ENT and opthalmology surgery specialists in 
Germany, for example, and the Workshop agreed this situation is suboptimal for both the 
patients and the physicians involved. This setting includes many clinicians appointed to posts 
in the 1990s and 2000s.  
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It is also vital to acknowledge and consider the experienced non-medical health care professionals 
(HCP) who support and add value to the optimal diagnosis and management of allergy in children.  
Countries differ in the training and utilisation of allied HCP within in the allergy teams. Specialist 
nursing and dietetic clinics already occur in some allergy centres in the UK and Scandinavia [2]. How-
ever, to date, the authors are unaware of an accredited curriculum and certification in allergy, alt-
hough ratified 2-year training programmes for asthma or eczema exist.  This issue could and should 
be addressed with the appropriate stakeholders. 
All delegates of the workshop have endorsed the concept that optimal care of children with allergic 
diseases is delivered by pediatricians who have received dedicated training in allergy, or allergists 
who have received dedicated training in pediatrics. Therefore, the proposed way forward is for only 
these specialists to be accredited to consult children with allergic diseases in the near future. None-
theless, the panel acknowledges the idiosyncrasies of each country’s specialty training programmes. 
Respect is given to the fact that there are allergists with general adult medicine as their background 
who have been seeing allergic children routinely, especially in light of the absence of pediatric aller-
gists in their country. On this basis and for the time being, doctors currently engaged in PA who have 
not undergone pediatric training but can demonstrate the necessary skills and competencies can still 
be considered to be accredited as pediatric allergologists, akin to the Grandfather clause that allows 
continuing practice for those appointed/ in post before formal accreditation processes were estab-
lished. In countries where PA is an acknowledged specialty or where there are EAP-certified PA cen-
tres, accreditation can take place through a formal application of the doctor to the PA national soci-
ety or PA centre of the country respectively. The role of the ETC-PA in individual certification of Eu-
ropean Specialists and Centre certification has been key to the development of PA in Europe. Alt-
hough not a legal licence to practice, this certification is an important asset to an individual CV, par-
ticularly in countries where PA does not officially exist and may also help to give visibility to the sub-
speciality and to influence its recognition. It is also a prerequisite to accredit training Centres, since 
teachers must be qualified and recognized as such. After international visitation and accreditation, 
all involved centres to date (6 in Spain and 7 in Sweden) agreed that this initiative led to an im-
provement in teaching quality, clinical quality, planning of training and training of techniques. 
Of note though, it is up to national bodies to acknowledge subspecialties and to define the rules for 
training centre accreditation and subspecialist certification in their countries. These rules should 
ideally be similar all over Europe.  In countries where a given subspecialty is not recognized, the in-
ternational certification of centres may play a crucial role in promoting the visibility and final recog-
nition of this field as a specialized area of medicine in that country.   
 
Education according to the EAP European Paediatric Allergology Training Programme  
The European Paediatric Allergology Training Programme was firstly approved in 1999 and revisions 
made until a consensus syllabus was approved in the end of 2016 [3]. It is one of the subspecialist 
training programmes in tertiary care paediatrics, defined by the Tertiary Care Group of EAP, itself 
the Paediatric section of the European Union of Medical Specialists (Union Européenne des 
Médecins Spécialistes - UEMS).  Based on this programme, pediatric allergists are expected to prac-
tice their skills and apply their expertise within the framework of a specialized Tertiary Care Unit. 
These specialists will also have the commitment of training general pediatricians and pediatricians 
with interest in PA. 
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According to this Training Programme, all doctors practicing PA require a prescribed and nationally 
accredited basic training in general pediatrics, as set out by many National Training Authorities, and 
the recommended European Common Trunk Syllabus, approved by the EAP-UEMS. This programme 
stipulates 3 years minimum in general pediatrics, serving as a prelude to PA. In some countries, a 
clinical training period of 24 months full-time employment in PA is considered adequate, but others 
require longer for accreditation.  
Nevertheless, the content or competencies demonstrated and not the length of education a priori 
should be the basis of PA subspecialty certification. A precise Training Syllabus [3] is detailed in the 
European Pediatric Allergology Training Programme. This is structured in modules, each containing 
training requirements in a specific area, expertise, or skill.  Simultaneous training in several modules 
is possible, according to local service and training configurations. Training can be completed with 
modules acquired in several different training centres, with at least one named, trainer-recognised 
primary centre. Immunology is regarded as an add-on module and in some countries a separate 
subspecialty. Immunodeficiencies are not officially included in the PA curriculum. 
Competency-based assessment, as an adjunct to knowledge assessment and portfolio completion, is 
an important aspect of evaluation. Several countries have recently reformed their postgraduate 
medical education and competencies should be evaluated throughout the training period. PA train-
ees are encouraged and required to keep a contemporaneous written log-book of patients they have 
seen, together with procedures conducted, and the therapeutic interventions instigated and fol-
lowed-up. This will constitute part of their portfolio.  
Research training is considered an essential aspect of the PA curriculum. Furthermore, attendance at 
International Congresses and giving 2-3 presentations in such meetings is highly recommended. 
 
Pediatric Allergy Exams 
A knowledge-based assessment is desirable and preferably included in a national final exam. EAACI 
is currently organising a modification of the EAACI Knowledge Exam which offers an official 
knowledge certificate for allergists/clinical immunologists. This modification will lead to a specific 
certification for pediatric allergists on a European and global level. This will impact on the implemen-
tation of structured pediatric allergy care in all European countries. In addition, it could offer an op-
tional replacement for the knowledge-based assessment of PA national certification, provided it is 
accepted by the relevant national authority. These EAACI Exams on PA are anticipated to help the 
harmonization of education and exchange of young doctors in the PA field across Europe. Moreover, 
this kind of certificate will be of value for national validation. While the exam may not replace the 
established training and rules for the specialty foreseen by each nation, this kind of certificate will be 
of value as an additional qualification.  
 
Networks for pediatric allergists across Europe 
In order to meet the needs of children and families with allergic disease(s), the pediatric allergist is 
highly encouraged to develop several networks (Figure 1). Engaging with different groups facilitates 
education, training, clear communication, creates the opportunity to develop shared pathways for 
patients, as well as for recruiting potential experts in the field. 
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i) Multi-disciplinary team (MDT) pediatric allergy clinics 
Pediatric subspecialty services are becoming increasingly multi-disciplinary. Proposed members of 
the allergy MDT include pediatric allergists, specialist nurses, dietitians and psychologists. The ideal 
is to have a “one stop shop” model where children and their families attend paediatric allergy clinics 
composed of MDT members. The skillset of the MDT is diverse and may overlap; generally, medical 
clinicians have overarching responsibility for patients, dietitians can guide exclusion diets and rein-
troductions as well as ensure the child’s nutrition is complete, and nurses usually support food and 
drug challenges, perform allergy tests, as well as ensure emergency plans are in place. In addition, 
nurses most often liaise with schools in order to ensure the child is safe in the community – this can 
involve visiting schools or training school nurses to recognize and treat allergic reactions. The roles 
of MDT members are expanding; many centres are developing nurse-led and dietetic-led clinics 
where clinically appropriate, which increases access for patients. This creates opportunities for fo-
cused and practical education and quality of life improvements. The ‘one-stop shop’ model makes 
holistic patient care more efficient. MDTs could be even broader and include liaison with allergy-
related pediatric subspecialties, such as ENT, respiratory, gastroenterology, dermatology and oph-
thalmology teams. There are centres which have set up joint clinics where patients are assessed by 
sub-specialists simultaneously – the provision of this service mostly depends on local resources.  
 
ii) Primary care 
In many European countries, the majority of patients with allergic disease(s) will consult first with 
their primary care giver [e.g. general practitioner (GP) in the UK, general pediatrician in Switzerland]. 
Remarkably, one third of all UK GP consultations in 2007 were due to allergic diseases. Although 
pediatric allergy networks and national societies are engaged and annual meetings well attended, 
they infrequently involve the primary care giver. Establishing links with primary care givers will cre-
ate opportunities - for education and training, as well as to facilitate prompt referrals and shared 
care for patients. Regional networks can be a way of involving primary care in continuous education 
and pediatric allergists must reach out to primary care where time for training might be scarce. Oth-
er initiatives include EAACI primary care symposia during EAACI meetings and adaptation of an 
EAACI masterclass in PA for primary care physicians. 
 
iii) Regional networks 
In some European countries, regional networks are increasingly popular, as they facilitate education 
and information dissemination among pediatric allergy MDT across the region. Tertiary centres tend 
to co-ordinate meetings, with attendance from MDT members from secondary care hospitals and 
occasionally by primary care. There is opportunity to collect regional data eg for asthma, food chal-
lenges, creating regional guidelines e.g. standardized food challenge, referral pathways for drug al-
lergy, or even to conduct audits. Most importantly, there is an opportunity to discuss cases, be it 
simple or complex, among experts from the tertiary centre. We strongly support the constitution of 
regional clinical networks led by trained and experienced pediatric allergists, and including physi-
cians and allied health professionals involved in the care of allergic children and adolescents. Clinical 
and research networks also need to focus on strategic partnerships and collaboration with adult 
colleagues to better understand how to support each other’s needs and to align activities. 
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iv) International networking 
Well-established PA centres can offer great support to centres in other countries where PA is emerg-
ing. Short, as well as longer term, visits to both sides of the network should be encouraged, not only 
for trainees, but also for established professionals. Moving to a country with a higher cost of living is 
a major problem impairing the ability to take up a training or sabbatical position. Fostering and sup-
porting the activities of pediatric allergists in their local centres as well as exchanges across clinical 
and research networks allows growth of expertise and sharing of ideas. With this in mind, it has 
been noted that fellowship grants and training opportunities should be available to those who are 
still or have just completed their training but no longer qualify for junior membership eg at EAACI. 
Similarly, consultants in post have expressed the wish to learn from other centres in a way which 
realistically allows useful networking and cross-pollination of ideas.  
Certification of PA centres for training through ETC-PA should be encouraged. Certified centres will 
be identified as resource centres for exchange, and will testify to a high level of clinical care. In addi-
tion, it is important to acknowledge centres that provide excellent clinical or research exposure to 
specific aspects of PA, to avoid oversubscription of well-known centres and to engage and develop 
new centres of excellence. 
 
v) Medical students and pediatric trainees 
Provision of allergy teaching within the undergraduate curriculum is variable throughout Europe. 
Medical schools might allocate a most commonly restricted time for undergraduate allergy-teaching. 
It is vital that undergraduate medical students are exposed to the specialty – this will stimulate in-
terest and enthusiasm in individuals who may become future specialists in the field. Similarly, allergy 
training should be offered to pediatric trainees in order to generate interest and recruitment into 
PA. 
 
vi) Social media and modern communication Apps 
Digital tools are useful for communication among healthcare professionals who provide pediatric 
allergy services. In Turkey, for instance, a closed WhatsApp group was created in order to facilitate 
case discussions among HCP who deal with children with allergic disease(s). 
Facebook is a popular platform for patients / families to interact. Similarly, Twitter has been gaining 
increasing interest the last years in the medical community as its users can: 
 A) follow a Journal’s latest articles (eg through the hashtag #PAI_Journal for all PAI papers) or many 
of the key messages presented in Meetings’ sessions (eg via #EAACI2017 for all twitter posts on the 
EAACI Congress 2017),  
B) participate in twitter discussions meant either for professionals (eg via #AboutAllergy for twitter 
discussions organized by EAACI) or patients and lay public (eg through #AllergyReady).  
These potentially powerful learning and communication tools also require some guidance for opti-
mal clinical conduct and governance and need to be identifiably distinct and separate from ungov-
erned patient/ parent sites which are not backed by science and medical expertise. For all infor-
mation in the public domain, strict patient confidentiality has to be adhered to, in accordance with 
local trust guidelines. EAACI has an annex dedicated to the proper use of social media by HCP as part 
of the EAACI code of ethics [4]. In time, there is likely to be a need for formal education on this in-
cluded as part of training. 
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vii) Media 
Pediatric allergology is a topic of wide interest to the media. Aside from social media, some may find 
it useful to engage with the traditional media of communication in order to ensure seamless dissem-
ination of the correct information. Effective and co-ordinated communication can avoid negative 
publicity due to fatalities, near-misses from food anaphylaxis, for example, or may be better pre-
sented as a result. Additionally, effective liaison with and through the media should be communicat-
ed at national and EU level aiming at promoting the prioritisation of allergic diseases. 
 
viii) Patient organisations 
Pediatric allergists engage with and support professional patient organisations in order to further 
support families. This creates an educational opportunity – ensuring that scientific information is 
understood by patients and families for better outcomes. 
 
ix) Pharmacists 
In addition to their knowledge of medicines, pharmacists also provide advice, information and 
treatment for a number of chronic conditions and play a vital part in health promotion and disease 
prevention initiatives. Pharmacists are educated to support patients manage medicines and their 
side effects effectively [5] while they contribute to improved patient adherence. Therefore, they are 
important liaisons for pediatric allergists and can further contribute to increased awareness of aller-
gic diseases. 
 
 
Current state and future of pediatric allergy research in Europe 
Recent years have seen significant advances in our understanding of allergenic pathophysiology and 
tolerance induction. Work is underway to assess the generalisability and feasibility of practical rec-
ommendations for optimal public health impact. There are also several new therapeutic drug op-
tions becoming available which need paediatric trials. With research opportunities in basic, transla-
tional, clinical, epidemiological and drug trials, more trainees and trained specialists are needed. It is 
certainly an exciting time to be a pediatric allergologist!  
 
Our challenge now is to develop a clear strategic approach to scientific excellence to across our 
member base, to ensure and enhance the relevance of European pediatric research in allergy (Table 
1). Several key areas for potential investment include:  
 
i) Prevention of allergic disease(s) 
Research is ongoing for the prevention of eczema, food or respiratory allergy, or required in the 
epidemiology of allergy; genetics, immunology, molecular and cellular mechanisms of the allergic 
immune response and for drugs suitable for children. 
Basic science research is underrepresented in pediatric medicine and this should be strategically 
highlighted to the EU and national funding agencies.  Recent studies have made significant inroads 
into understanding the pathophysiology of tolerance induction, as well as the specifics of primary 
food allergy prevention. These messages necessarily lead to further epidemiological and clinical 
translational and intervention studies. Pediatric medicine is a fertile research ground for cohort stud-
ies but, for reasons not fully explored in the remit of this paper, it has been historically weak on trials 
and this is due to change. 
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ii) Diagnostic tools and management in PA 
Better child and young person-centric diagnostic tools are needed to avoid misdiagnosis or unneces-
sary positive challenges. In vitro diagnostics appear promising with respect to predicting positive 
food or drug challenges, but there is much work to be done in relation to easier and accurate diag-
nosis of non-IgE allergy. Research in diagnostic biomarkers also needs to take into account if, and 
how, the potentially different physiology of children is important at different age-ranges. Accurate 
and earlier diagnostics for allergic diseases and risk of development would help prevent missing the 
window of opportunity and thus optimise chances of primary and secondary prevention. 
At the same time, effective research in drug allergy in children - and more effective means of navi-
gating difficult and slow processes related to drug research in children - is much needed. An example 
of important public health intervention resulting from such research is the removal of pholcodeine 
from over the counter products, such as children cough syrups. The wide-scale reduction in exposure 
to this allergen means potentially fatal anaphylactic reactions to neuromuscular blocking drugs may 
be prevented. 
Allergen specific immunotherapy (AIT), first described in 1908, has recently been rejuvenated with 
respect to oral, epicutaneous, sublingual or subcutaneous modalities for food allergy as well as with 
the introduction of peptides instead of whole extracts against allergic rhinitis [6].  More child-
friendly and better access to AIT is required, as is better standardisation and training. Ongoing sur-
veillance of adverse side effects and tolerability as regards quality of life is imperative.  
 
i) New drug development and trials for paediatric safety and efficacy 
It is known that drugs for neonates, infants and very young children need to be reviewed with re-
spect to drug absorption, distribution, metabolism and excretion and the implication on drug usage, 
especially dose. However, for older children, despite acknowledgement that brain maturation may 
take till up to 25 years, characteristics may be as for adults. Of note though, EU pediatric regulation 
requires a paediatric investigation plan (PIP) for every new drug as a condition for marketing ap-
proval.  
It is important to discuss that AIT products in the EU were exposed to two key legislations in 
2007/2008: a requirement for PIP submission, and the German therapy allergen ordinance [7]. The 
latter made it mandatory for manufacturers to register every AIT product, despite being in use for 
decades. As Germany is the largest market for AIT products, this affected all allergen AIT manufac-
turers in Europe. More than a hundred PIPs were submitted in short time, resulting finally in a mas-
sive study programme proposed to involve 58 five-year double blind randomized placebo-controlled 
allergen AIT safety & efficacy trials with several hundred participants. The deadline for these studies 
is December 2031. While aspects of current AIT products on the market need appropriate study and 
review, there is concern that the requirement for participation of thousands of children and adoles-
cents potentially leaves children at risk of unnecessary morbidity and, those assigned to placebo 
groups, at risk of progression or march of allergic disease.  
Many clinical specialists are unaware of this issue and would rationally question the necessity of 
trials which would hold up the ability of children to benefit from medications that have been proven 
to be of benefit in adults. The PIP system is due for discussion in the EU parliament, and it is hoped 
that representatives from PA and EAACI will raise their voice together with those from other pediat-
ric specialties [8] to review the EMA's position which risks suffocating pharmaceutical innovation. 
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ii) Innovation and technology 
Innovation and technology for better personalised clinical care, public health and research tools is a 
growing and rapidly changing field. EAACI is already cognisant of this fact and a mobile-health task-
force has been created to evaluate and develop the organisation’s approach. The promise is of more 
effective tools to monitor patients, to educate patients or professionals and to improve adherence. 
These potential benefits need to be rigorously evaluated to assess the true impact and whether or 
not the mobile health or digital tools are indeed effective in improving education, adherence and 
self-efficacy in the management of allergic diseases. Collaboration and engagement with primary 
care and public health as well as extra pediatric groups, such as health economists and appropriately 
skilled tech expertise will be required to inform assessment and trials. 
 
iii) Improved strategic communication and collaboration 
Improved strategic communication and collaboration is related to public health, economists, regula-
tory bodies, the lay public and the press. Pediatric allergists must be strong advocates for their pa-
tients. 
 
iv) Fostering Networks for research 
The need for the development of pan-European registries to facilitate research and care was high-
lighted in an EAACI statement by Professor Papadopoulos et al in 2012 [9]. As an example of the 
valuable information a registry can carry, the European Anaphylaxis Registry has recently provided 
significant epidemiological information on the eliciting factors of anaphylaxis in children and adoles-
cents [10].  
At the same time, a key area for development is the identification of clinical centres involved or in-
terested in the care and research work in PA. They will represent a platform for research collabora-
tion and communication in the form of registers or clinical networks. Currently, these arise on an ad 
hoc basis for studies, but maintained networks with established leads and contact points are likely to 
facilitate research integration into clinical practice both in the study phase and at implementation of 
new guidance. A drug allergy network exists currently.  
 
Planning ahead 
A strategic plan to enhance PA as a specialty should focus on its unique strengths and aim to mini-
mise its weaknesses. A focus on pediatrics and on primary, secondary and tertiary prevention also 
favours health promotion and cost-effectiveness of EU health systems. PA requires a defined exper-
tise, while immense research and increased interest is taking place in this field. PA, as a pediatric 
subspecialty, has the gratifying ability to intervene early and to improve health and quality of life of 
allergic children, adolescents, and their families, over the long term. Nonetheless, pediatric 
allergology is currently not recognised in all countries, and there is a lack of visibility and awareness 
of the benefits of implementing this subspecialty. The wide diversity between nations and the dif-
ferential approach of health implementation priorities will continue to be a basis of weaknesses for 
PA. 
Opportunities are emerging from the rising number of allergic children and PA has the possibility to 
modulate disease progression and, potentially, to provide primary prevention. Allergy at all ages is 
still under-recognised as a health issue by other specialties, as well as by government bodies and this 
has adverse implications for health and research budgets.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Journals publishing on paediatric allergy should inspire and demand quality and timely research by 
ensuring high acceptance standards, critical expert reviews, rapid turnaround times, and electronic 
publication. 
In order to ensure a positive future for groundbreaking pediatric allergy research, the roadmap 
ahead should provide mentorship and support for juniors, as well as for established researchers. The 
appropriate signposting of existing support and resources including specific expertise, mentoring 
and research post and funding opportunities is essential. The role and importance of national mem-
ber organisations is key to the grassroots support and growth of these ideas and the promotion of 
and for paediatrics in allergy clinical guidance, training, research and policy. EAACI and other Europe-
wide or international organisations need to provide strategic support to pediatric inclusion in these 
spheres and EAACI already actively support the inclusion of meaningful pediatric recommendations 
in their guideline work. 
 
 
Conclusion 
PA as a sub-specialty is being better recognised and a universally acceptable standard for training 
and accreditation is being refined. Original research should be promoted, as well as outstanding 
review articles for key topics. The rapid publication of meeting reports, with the aim to provide both 
an overview and a discussion of the latest advances presented in pediatric research would be wel-
comed.  
The role for EAACI, and similar organisations world-wide who wish to prioritise the agenda for PA 
needs to include: broadening of national representation, lobbying for recognition across stakeholder 
countries, the free movement of realistically funded specialists in training and accurate and well-
communicated reports on the economic benefits of disease control and prevention for commission-
ers, policy and funding bodies. These efforts ultimately have one aim - to improve the health and 
quality of life of children predisposed to and suffering with allergic disease.  
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Figure 1, legend: Networks for pediatric allergists across Europe  
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